INTS News

Intensity Therapeutics, Inc. to Present INVINCIBLE-4 Neoadjuvant Triple-Negative Breast Cancer Study Data for the First Seven (7) Patients After INT230-6 Treatment (Cohort A) in an ePoster Presentation at the European Society of Medical Oncology (ESMO) Meeting Intensity Therapeutics, Inc. to...

Intensity Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference Intensity Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference PR Newswire SHELTON, Conn., Sept. 8, 2026 SHELTON, Conn., Sept. 8, 2026 /PRNewswire...

DENVER, Colo. ( 247marketnews.com ) — NeOnc Technologies (NASDAQ:NTHI) is heading into Wednesday with the kind of setup that can put a clinical-stage biotech squarely on the market’s radar: a stock tr...

Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update PR Newswire SHELTON, Conn., Aug. 11, 2026 Initiated activities to resume enrollment in a limited number...

Intensity Therapeutics to Announce Second Quarter 2026 Financial Results on August 11, 2026 Intensity Therapeutics to Announce Second Quarter 2026 Financial Results on August 11, 2026 PR Newswire SHELTON, Conn., Aug. 4, 2026 Company to hold a conference call at 8AM ET on August 11, 2026 to review...

Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study) Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical...

Intensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6 Intensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6 PR...

Intensity Therapeutics Inc. (INTS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Intensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical Award Intensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical Award PR Newswire...